D3 Bio Inc. has obtained IND clearance from the FDA for D3S‑003, enabling initiation of a first‑in‑human phase I trial in patients with advanced solid tumors harboring KRAS G12D mutations.
Scientists at Healzen Therapeutics Co. Ltd. and Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have described GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Université de Montréal has disclosed GTPase KRAS G12D mutant inhibitors reported to be useful for the treatment of cancer, inflammatory disorders and immunological disorders.
Scientists from Shanghai Zelgen Pharmatech Co. Ltd., Suzhou Zelgen Biosciences Co. Ltd. and Zejing Pharmaceutical (Zhejiang) Co. Ltd. have presented GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Jacobio Pharmaceuticals Co. Ltd. has reported new fused tetracyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors potentially useful for the treatment of cancer.
